Precision BioSciences Inc

Financials

Cash from operating activities -87.39 M-10.85 M-45.75 M-84.11 M-58.45 M-65.84 M -65.84 M Cash from investing activities -5.03 M-5.8 M-3.32 M5.83 M-215 K-634 K -634 K Cash from financing activities 1.33 M70.52 M94.98 M5.39 M50.45 M95.16 M 95.16 M Free cash flow -92.42 M-15.91 M-49.07 M-86.07 M-58.7 M-65.93 M -65.93 M

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

DTIL

Financials

Precision BioSciences Inc

Notícias

Should You Buy Precision BioSciences (DTIL) After Golden Cross?

Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call - Slideshow (NASDAQ:DTIL) 2026-03-18

Jones Trading reitera classificação das ações da Precision BioSciences após design do estudo de DMD

Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript

Jefferies reduz preço-alvo da Precision BioSciences

Jefferies cuts Precision BioSciences stock price target on valuation

Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates

Precision BioSciences recebe aprovações de patentes para programa de hepatite B

Precision BioSciences receives patent allowances for hepatitis B program

Precision BioSciences apresenta dados pré-clínicos sobre terapia para DMD

Precision BioSciences presents preclinical data on DMD therapy

Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates